• Explore /
  • Poster
  • / SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with <em>EGFR</em>-mutant, <em>MET</em>-driven (<em>MET</em>+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.

SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell lung cancer (NSCLC), following disease progression on osimertinib.

Abstract Poster

Authors

Geoffrey Oxnard

Geoffrey R. Oxnard

Dana-Farber Cancer Institute, Boston, MA

Geoffrey R. Oxnard , Mireille Cantarini , Paul Frewer , George Hawkins , Jane Peters , Paul Howarth , Ghada F. Ahmed , Tarjinder Sahota , Ryan Hartmaier , Xiaocheng Li-Sucholeiki , Myung-Ju Ahn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03778229

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS9119)

DOI

10.1200/JCO.2019.37.15_suppl.TPS9119

Abstract #

TPS9119

Poster Bd #

439b

Abstract Disclosures

Similar Posters

First Author: Caicun Zhou

First Author: Jonathan N. Priantti

Poster

2023 ASCO Annual Meeting

Uncommon <i>EGFR</i> mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.

Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.

First Author: Yusuke Okuma

First Author: Daniel Adam Breadner